For adults with moderate to severe hidradenitis suppurativa
COSENTYX® (secukinumab) IS THE FIRST MEDICINE OF ITS KIND† FOR ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA (HS)
Looking for an HS treatment with proven experience?
1st
COSENTYX is the first treatment of its kind† that targets IL-17A, a molecule thought to play a role in causing inflammation that contributes to HS symptoms. The way COSENTYX works in the body and how it affects HS symptoms is not fully known.
4.3+ MILLION
Before the FDA approved COSENTYX to treat adults with moderate to severe HS, over 4.3 million COSENTYX prescriptions had been filled‡ in the United States across all indications combined (not including HS).
16 YEARS
COSENTYX has been extensively studied for over 16 years across 8 conditions.
†COSENTYX targets and blocks IL-17A, a molecule thought to play a role in the inflammation that may contribute to HS symptoms.
‡As of December 2023.
COSENTYX has had a well-studied safety profile since its launch in 2015 and has been approved to treat numerous conditions:
2015 — adults with moderate to severe plaque psoriasis
2016 — adults with active ankylosing spondylitis and active psoriatic arthritis
2020 — adults with active non-radiographic axial spondyloarthritis
2021 — children with plaque psoriasis (6 years and older), psoriatic arthritis (2 years and older), and enthesitis-related arthritis (4 years and older)
2023 — adults with moderate to severe hidradenitis suppurativa
